J Gynecol Oncol.  2014 Jan;25(1):3-5. 10.3802/jgo.2014.25.1.3.

Cervical preneoplasia biomarkers: a conundrum for the community based gynecologic surgical pathologist

• van Bogaert LJ

• KMID: 1811180
• DOI: http://doi.org/10.3802/jgo.2014.25.1.3

Abstract

The integration of high-risk (HR) human papillomavirus (HPV) in the cell genome is an essential step in the oncogenic pathway of lower ano-genital HPV-related squamous preinvasive and invasive lesions. The expression of HR-HPV surrogate biomarkers of HR-HPV integration by immunohistocytochemistry (IHC) serves as a diagnostic and/or a prognostic tool of cervical preinvasive lesions. IHC is claimed to decrease the interobserver variability in the diagnosis of histomorphologically equivocal lesions, and to be helpful in evaluating the potentiality of regression, persistence or progression. The most common biomarkers used in cervical pathology are p16(INK4a), Ki-67, the HPV capsid L1 antigen, and ProEXc. Critical review of the literature shows a great variability in the diagnostic accuracy, risk evaluation, and relative distribution of these biomarkers in low and high grade preinvasive lesions. Review of the literature suggests that currently dual IHC with p16 and L1 provide the best diagnostic and prognostic evaluation of lesions diagnosed histomorphologically as low and high-grade.

Keyword

Biomarkers; Cervix uteri; Preinvasive lesions

MeSH Terms

Biological Markers*
Capsid
Cervix Uteri
Cyclin-Dependent Kinase Inhibitor p16
Diagnosis
Female
Genome
Humans
Immunohistochemistry
Leukocyte L1 Antigen Complex
Observer Variation
Pathology
Biological Markers
Cyclin-Dependent Kinase Inhibitor p16
Leukocyte L1 Antigen Complex

Reference

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189:12–19.

2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348:518–527.

3. Steenbergen RD, de Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ. HPV-mediated transformation of the anogenital tract. J Clin Virol. 2005; 32:Suppl 1. S25–S33.

4. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999; 59:6132–6136.

5. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001; 92:276–284.

6. Hopman AH, Smedts F, Dignef W, Ummelen M, Sonke G, Mravunac M, et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol. 2004; 202:23–33.

7. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol. 2006; 44:1755–1762.

8. Ho CM, Cheng WF, Chu TY, Chen CA, Chuang MH, Chang SF, et al. Human papillomaviral load changes in low-grade squamous intraepithelial lesions of the uterine cervix. Br J Cancer. 2006; 95:1384–1389.

9. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012; 136:1266–1297.

10. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007; 127:805–815.

11. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R, et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010; 133:395–406.

12. Kostopoulou E, Koukoulis G. Ancillary techniques in the histopathologic diagnosis of squamous and glandular intraepithelial lesions of the uterine cervix. In : Broeck DV, editor. Human papillomavirus and related diseases from bench to bedside: a diagnostic and preventive perspective. Rijeka, Croatia: InTech;2013. http://dx.doi.org/10.5772/55897.

13. Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer. 2008; 114:83–88.

14. Choi YS, Kang WD, Kim SM, Choi YD, Nam JH, Park CS, et al. Human papillomavirus L1 capsid protein and human papillomavirus type 16 as prognostic markers in cervical intraepithelial neoplasia 1. Int J Gynecol Cancer. 2010; 20:288–293.

15. Stemberger-Papic S, Vrdoljak-Mozetic D, Ostojic DV, Rubesa-Mihaljevic R, Manestar M. Evaluation of the HPV L1 capsid protein in prognosis of mild and moderate dysplasia of the cervix uteri. Coll Antropol. 2010; 34:419–423.

16. Ungureanu C, Socolov D, Anton G, Mihailovici MS, Teleman S. Immunocytochemical expression of p16INK4a and HPV L1 capsid proteins as predictive markers of the cervical lesions progression risk. Rom J Morphol Embryol. 2010; 51:497–503.

17. van Bogaert LJ. P16INK4a immunocytochemistry/immunohistochemistry: need for scoring uniformization to be clinically useful in gynecological pathology. Ann Diagn Pathol. 2012; 16:422–426.